{
    "clinical_study": {
        "@rank": "8280", 
        "arm_group": [
            {
                "arm_group_label": "Intensive adherence instruction", 
                "arm_group_type": "Experimental", 
                "description": "Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Sham Comparator", 
                "description": "The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the influence of the instruction on the use of\n      Aricept with educational brochure on the 48-week medication persistence and to assess the\n      reasons for discontinuation."
        }, 
        "brief_title": "Intensive Instruction on the Use of Aricept", 
        "condition": "Alzheimer's Type Dementia", 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Dementia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnostic evidence of probable Alzheimer's type Dementia consistent with DSM-IV.\n\n          -  Written informed consent will be obtained from subject (if possible) or from the\n             subject's legal guardian or other representative (according to Japanese regulations\n             as appropriate) prior to beginning screening activities.\n\n          -  Patients having caregivers who submit written consent for cooperative involvement in\n             this study, can provide patients' information necessary for this study, assist\n             treatment compliance, and escort patients on required visits to study institution.\n\n          -  Outpatients in their own home.\n\n        Exclusion Criteria:\n\n          -  Patients treated with donepezil, galantamine, rivastigmine in 4 weeks immediately\n             before enrollment.\n\n          -  Known hypersensitivity to donepezil or piperidine derivatives.\n\n          -  Involvement in any other investigational drug clinical trail during the preceding 12\n             weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972204", 
            "org_study_id": "ART-2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intensive adherence instruction", 
                "description": "Instruction with educational brochure", 
                "intervention_name": "Intensive adherence instruction", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Instruction as per usual practice", 
                "intervention_name": "Control", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Donepezil"
        }, 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tsujidoukandai 1-5-1", 
                    "country": "Japan", 
                    "state": "Fujisawa-City, Kanagawa"
                }, 
                "name": "Shonan Fujisawa Tokushukai Hospital"
            }, 
            "investigator": {
                "last_name": "Tetsumasa Kamei", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study About the Impact of Intensive Instruction on the Use of Aricept and the Reasons for Discontinuation in Patients With Alzheimer's Disease", 
        "overall_contact": {
            "email": "machida@mirai-iryo.com", 
            "last_name": "Tomoko Machida", 
            "phone": "+81-3-3263-4801"
        }, 
        "overall_official": {
            "affiliation": "Shonan Fujisawa Tokushukai Hospital", 
            "last_name": "Tetsumasa Kamei", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Medication persistence rate", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Reasons for discontinuation", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972204"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mirai Iryo Research Center, Inc.", 
            "investigator_full_name": "Tetsumasa Kamei", 
            "investigator_title": "Hospital Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Subgroup analysis with delineation of different factors associated with the degree of medication persistence with Aricept therapy: years of schooling, family living together, caregiver background, Category of Condition of Need for Long-Term Care, In-Home Long-Term Care Service, FAST, MMSE-J, the Level fo Independent Living of Demented Elderly, concomitant medication, BPSD, drug compliance", 
                "measure": "Factor analysis for medication persistence", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Week 2, 12, 24, 48"
            }
        ], 
        "source": "Mirai Iryo Research Center, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mirai Iryo Research Center, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}